Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification
- PMID: 36527335
- DOI: 10.1111/nan.12870
Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification
Abstract
Aims: Pituitary neuroendocrine tumour (PitNET)/adenoma classification is based on cell lineage and requires immunopositivity for adenohypophysial hormones and/or transcription factors (TFs) steroidogenic factor 1 (SF1), T-box transcription factor TBX19 (TPIT) or pituitary-specific positive transcription factor 1 (PIT1). PitNET/adenomas lacking lineage affiliation are termed 'null cell' tumours (NCTs). NCT diagnosis may be afflicted by methodological limitations and inconsistent diagnostic approaches. Previous studies have questioned the existence of true NCTs. In this study, we explore the epigenomic identities of PitNET/adenomas lacking clear TF immunopositivity.
Methods: Seventy-four hormone-negative PitNET/adenomas were immunostained and scored for SF1, TPIT and PIT1 expression. All tumours were classified as gonadotroph, corticotroph, PIT1-positive or 'null cell'. NCTs were subjected to global DNA methylation analysis. Epigenomic profiles of NCTs were compared to reference tumours using Uniform Manifold Approximation and Projection (UMAP) plotting and methylation-based classification.
Results: TF immunostaining revealed definite lineage identity in 59 of 74 (79.7%) hormone-negative PitNET/adenomas. Of the remaining 15 NCTs, 13 demonstrated minimal and inconclusive nuclear SF1 or TPIT expression (5 and 8, respectively). Two NCTs were entirely immunonegative. UMAP plotting and methylation-based classification demonstrated that the epigenomes of NCTs with minimal SF1 or TPIT expression were adequately affiliated with gonadotroph or corticotroph lineages, respectively. The two immunonegative NCTs were located near the corticotroph PitNET/adenomas via UMAP, whereas the methylation classifier could not match these two cases to predefined tumour classes.
Conclusions: Epigenomic analyses substantiate lineage identification based on minimal TF immunopositivity in PitNET/adenomas. This strategy dramatically decreases the incidence of NCTs and further challenges the legitimacy of NCTs as a distinct PitNET/adenoma subtype. Our study may be useful for guiding diagnostic efforts and future considerations of PitNET/adenoma classification.
Keywords: DNA methylation; copy number profile; null cell; pituitary adenoma; pituitary neuroendocrine tumour.
© 2022 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.
Similar articles
-
Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.Acta Neuropathol. 2024 Jan 16;147(1):16. doi: 10.1007/s00401-024-02686-1. Acta Neuropathol. 2024. PMID: 38228887 Free PMC article.
-
Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.Hum Pathol. 2021 Apr;110:20-30. doi: 10.1016/j.humpath.2020.12.001. Epub 2020 Dec 13. Hum Pathol. 2021. PMID: 33321163
-
A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.Front Endocrinol (Lausanne). 2024 May 2;15:1368944. doi: 10.3389/fendo.2024.1368944. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38756997 Free PMC article.
-
Overview of the 2022 WHO Classification of Pituitary Tumors.Endocr Pathol. 2022 Mar;33(1):6-26. doi: 10.1007/s12022-022-09703-7. Epub 2022 Mar 15. Endocr Pathol. 2022. PMID: 35291028 Review.
-
Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives.Curr Med Sci. 2022 Dec;42(6):1111-1118. doi: 10.1007/s11596-022-2673-6. Epub 2022 Dec 22. Curr Med Sci. 2022. PMID: 36544040 Review.
Cited by
-
Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.Brain Tumor Pathol. 2023 Jul;40(3):158-162. doi: 10.1007/s10014-023-00462-9. Epub 2023 Apr 18. Brain Tumor Pathol. 2023. PMID: 37072666
-
Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.Acta Neuropathol. 2024 Jan 16;147(1):16. doi: 10.1007/s00401-024-02686-1. Acta Neuropathol. 2024. PMID: 38228887 Free PMC article.
-
Comparative epigenomics indicate a common origin of ectopic and intrasellar corticotroph pituitary neuroendocrine tumors/adenomas: a case report.Virchows Arch. 2024 Feb 12. doi: 10.1007/s00428-024-03760-5. Online ahead of print. Virchows Arch. 2024. PMID: 38347267
-
Pathological characteristics of reoperated regrowing clinically nonfunctioning pituitary tumor cases in comparison with initial surgical cases.Front Endocrinol (Lausanne). 2024 May 28;15:1400671. doi: 10.3389/fendo.2024.1400671. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38863935 Free PMC article.
References
REFERENCES
-
- Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521-535. doi:10.1007/s00401-017-1769-8
-
- WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours [internet]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2022 Apr 24]. (WHO classification of tumours series, 5th ed.; vol. 8). https://tumourclassification.iarc.who.int/chapters/36
-
- Balogun JA, Monsalves E, Juraschka K, et al. Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr Pathol. 2015;26(1):63-70. doi:10.1007/s12022-014-9347-2
-
- Haddad AF, Young JS, Oh T, et al. Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. Neurosurg Focus. 2020;48(6):E13. doi:10.3171/2020.3.FOCUS20114
-
- Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab. 2019;104(7):2473-2489. doi:10.1210/jc.2018-00688
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous